State Street’s INmune Bio INMB Stock Holding History

State Street’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$152K	Sell	93,363 -197,516	-68%	-$273K	﹤0.01%	3894
2026 Q1	$329K	Sell	290,879 -56,380	-16%	-$80.3K	﹤0.01%	3758
2025 Q4	$542K	Buy	347,259 +63,426	+22%	+$113K	﹤0.01%	3657
2025 Q3	$588K	Buy	283,833 +8,441	+3%	+$19.3K	﹤0.01%	3624
2025 Q2	$636K	Buy	275,392 +39,264	+17%	+$288K	﹤0.01%	3573
2025 Q1	$1.84M	Buy	236,128 +9,700	+4%	+$77K	﹤0.01%	3274
2024 Q4	$1.06M	Hold	226,428	–	–	﹤0.01%	3482
2024 Q3	$1.22M	Buy	226,428 +58,838	+35%	+$418K	﹤0.01%	3451
2024 Q2	$1.48M	Buy	167,590 +122,527	+272%	+$1.21M	﹤0.01%	3412
2024 Q1	$529K	Hold	45,063	–	–	﹤0.01%	3630
2023 Q4	$507K	Buy	45,063 +100	+0.2%	+$838	﹤0.01%	3638
2023 Q3	$308K	Hold	44,963	–	–	﹤0.01%	3805
2023 Q2	$408K	Hold	44,963	–	–	﹤0.01%	3743
2023 Q1	$290K	Hold	44,963	–	–	﹤0.01%	3939
2022 Q4	$285K	Hold	44,963	–	–	﹤0.01%	3968
2022 Q3	$279K	Hold	44,963	–	–	﹤0.01%	3995
2022 Q2	$397K	Buy	44,963 +7,300	+19%	+$54.3K	﹤0.01%	3927
2022 Q1	$317K	Buy	37,663 +3,847	+11%	+$34.5K	﹤0.01%	4222
2021 Q4	$345K	Buy	33,816 +6,100	+22%	+$90.3K	﹤0.01%	4142
2021 Q3	$538K	Sell	27,716 -7,100	-20%	-$137K	﹤0.01%	3942
2021 Q2	$612K	Buy	+34,816	New	+$469K	﹤0.01%	3791

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street's INMB Position: Q2 2026 in Review

State Street reduced its INmune Bio (INMB) stake by 68% in Q2 2026, selling an estimated $273K and leaving 93,363 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #3894.

State Street first reported a position in INMB in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.84M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

State Street held 93,363 shares of INmune Bio worth $152K as of Q2 2026.
State Street sold 197,516 INmune Bio shares in Q2 2026, an estimated $273K.
INmune Bio made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3894 holding.
State Street first reported a position in INmune Bio in Q2 2021 and has held it in 21 quarters since.
State Street's INmune Bio position peaked at $1.84M in Q1 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.